InsiderTrades

Form 4 for IMAX IMAX CORP

Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001214659-25-000204 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-01-06 2025-01-02 IMAX GELFOND RICHARD L CEO, Dir F - Tax $25.11 -97.2K 548.6K -15% -$2.44M
DM 2025-01-06 2025-01-02 IMAX GELFOND RICHARD L CEO, Dir M - OptEx $0.00 +175.1K 577.0K +44% $0
D 2025-01-06 2025-01-02 IMAX GELFOND RICHARD L CEO, Dir A - Grant $0.00 -109.5K 109.5K -50% $0
DM 2025-01-06 2025-01-02 IMAX GELFOND RICHARD L CEO, Dir M - OptEx $0.00 -175.1K 123.4K -59% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common common shares 2025-01-02 F D 33,840 $25.11 603,500 D — — (F2) Mr. Gelfond is reporting the withholding of common shares by IMAX Corporation to satisfy the tax withholding obligation in connection with the delivery of common shares upon conversion of the restricted share unit transaction.
2 Common common shares 2025-01-02 M A 61,192 $0.00 637,340 D — — (F1) Represents the conversion of vested restricted share units into common shares.
3 Common common shares 2025-01-02 F D 34,957 $25.11 576,148 D — — (F2) Mr. Gelfond is reporting the withholding of common shares by IMAX Corporation to satisfy the tax withholding obligation in connection with the delivery of common shares upon conversion of the restricted share unit transaction.
4 Common common shares 2025-01-02 M A 62,528 $0.00 611,105 D — — (F1) Represents the conversion of vested restricted share units into common shares.
5 Common common shares 2025-01-02 M A 51,383 $0.00 576,992 D — — (F1) Represents the conversion of vested restricted share units into common shares.
6 Common common shares 2025-01-02 F D 28,415 $25.11 548,577 D — — (F2) Mr. Gelfond is reporting the withholding of common shares by IMAX Corporation to satisfy the tax withholding obligation in connection with the delivery of common shares upon conversion of the restricted share unit transaction.
7 Derivative restricted share units 2025-01-02 A D 109,518 $0.00 109,518 D $0.00 · — to — 109,518 common shares (F3) Each restricted share unit represents a contingent right to receive one common share of IMAX Corporation. (F4) Each restricted share unit is the economic equivalent of one common share of IMAX Corporation. (F6) This represents the number of restricted share units for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,818,695; 294,433 and 603,500 respectively. The number of outstanding options reflects the expiration of options to purchase 467,625 common shares on January 5, 2025. Mr. Gelfond did not receive any value in connection with such expiration; therefore, such expiration is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, under Rule 16b-6(d). (F7) The restricted share units vest and will be converted to common shares in three installments: 36,506 on each of January 2, 2026, January 2, 2027 and January 2, 2028.
8 Derivative restricted share units 2025-01-02 M D 62,528 $0.00 62,529 D $0.00 · — to — 62,528 common shares (F3) Each restricted share unit represents a contingent right to receive one common share of IMAX Corporation. (F1) Represents the conversion of vested restricted share units into common shares. (F4) Each restricted share unit is the economic equivalent of one common share of IMAX Corporation. (F6) This represents the number of restricted share units for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,818,695; 294,433 and 603,500 respectively. The number of outstanding options reflects the expiration of options to purchase 467,625 common shares on January 5, 2025. Mr. Gelfond did not receive any value in connection with such expiration; therefore, such expiration is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, under Rule 16b-6(d). (F5) The restricted share units vested and converted to common shares on January 2, 2025.
9 Derivative restricted share units 2025-01-02 M D 51,383 $0.00 0 D $0.00 · — to — 51,383 common shares (F3) Each restricted share unit represents a contingent right to receive one common share of IMAX Corporation. (F1) Represents the conversion of vested restricted share units into common shares. (F4) Each restricted share unit is the economic equivalent of one common share of IMAX Corporation. (F6) This represents the number of restricted share units for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,818,695; 294,433 and 603,500 respectively. The number of outstanding options reflects the expiration of options to purchase 467,625 common shares on January 5, 2025. Mr. Gelfond did not receive any value in connection with such expiration; therefore, such expiration is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, under Rule 16b-6(d). (F5) The restricted share units vested and converted to common shares on January 2, 2025.
10 Derivative restricted share units 2025-01-02 M D 61,192 $0.00 123,386 D $0.00 · — to — 61,192 common shares (F3) Each restricted share unit represents a contingent right to receive one common share of IMAX Corporation. (F4) Each restricted share unit is the economic equivalent of one common share of IMAX Corporation. (F6) This represents the number of restricted share units for this transaction only. Mr. Gelfond's aggregate remaining outstanding option, restricted share unit and common share balances following these transactions will be 1,818,695; 294,433 and 603,500 respectively. The number of outstanding options reflects the expiration of options to purchase 467,625 common shares on January 5, 2025. Mr. Gelfond did not receive any value in connection with such expiration; therefore, such expiration is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, under Rule 16b-6(d). (F5) The restricted share units vested and converted to common shares on January 2, 2025.